Skip to main content
. 2021 Mar 12;11:554961. doi: 10.3389/fphar.2020.554961

FIGURE 2.

FIGURE 2

Selective sEH inhibitor t-AUCB, selective PPARγ agonist Rosiglitazone (top), and dual sEH/PPARγ modulators.